← SynDRA
IVOSIDENIB
SynDRA canonical compound SYN0039178 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | IDH1 |
|---|
| Mechanism of action | isocitrate dehydrogenase inhibitor |
|---|
| Indication | acute myeloid leukemia (AML) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
Mechanisms of action (all sources)
- IDH1 INHIBITOR
- Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
- isocitrate dehydrogenase inhibitor
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Cytochrome P450 3A4 Inducers
- Cytochrome P450 2C9 Inducers
- Isocitrate Dehydrogenase 1 Inhibitor
- Isocitrate Dehydrogenase 1 Inhibitors
ATC classes
- L01X · OTHER ANTINEOPLASTIC AGENTS
Cross-references
Synonyms
- tibsovo
- AG-120
- Tibsovo
- UNII-Q2PCN8MAM6
- Q2PCN8MAM6
- Ivosidenib [INN]
- Ivosidenib [USAN]
- Ivosidenib [WHO-DD]
- GTPL9217
- SCHEMBL15122512
- EX-A992
- MolPort-044-560-317
- RG120
- s8206
- 1448347-49-6 (Ivosidenib)
- AKOS028113340
- ZINC205136523
- CS-5122
- AS-35058
- HY-18767
- AG 120
- AG120
- ivosidenibum
- CHEBI:145430
- RefChem:57058
- L01XX62
- DTXCID801513494
- MFCD29036964
- Ivosidenib [USAN:INN:WHO-DD]
- C28H22ClF3N6O3
- Tibsovo (TN)
- IVOSIDENIB [MI]
- Ivosidenib (JAN/USAN/INN)
- orb1303993
- IVOSIDENIB [ORANGE BOOK]
- SCHEMBL29598134
- SCHEMBL29599627
- WIJZXSAJMHAVGX-DHLKQENFSA-N
Reported adverse events
- MDS
- Abdominal pain
- Alanine aminotransferase increased
- Arthralgia
- Ascites
- Aspartate aminotransferase
- Aspartate aminotransferase increased
- Chest pain
- Constipation
- Cough
- Dizziness
- Dyspepsia
Look up IVOSIDENIB in the interactive SynDRA portal →